BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, March 21, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 13, 2007

View Archived Issues

Carfilzomib well tolerated in consecutive-day schedule in hematologic malignancies

Read More

New preclinical and clinical data detail antithrombotic effects of YM-150

Read More

Novo Nordisk reports results for the third quarter 2007

Read More

Preclinical studies of anti-DKK1 mAb show potential for multiple myeloma therapy

Read More

Pooled trial data confirm eculizumab efficacy in paroxysmal nocturnal hemoglobinuria

Read More

Rivaroxaban thromboprophylaxis effective after hip replacement surgery

Read More

Bv8 promotes tumor growth through angiogenesis

Read More

New therapeutic agents for neurological disorders reported in recent patents

Read More

BioLineRx enters license agreement with Innovative Pharmaceutical Concepts for BL-5010

Read More

BioCancell reports successful experimental treatment using BC-819 for ovarian cancer

Read More

BioInvent designates BI-505 for blood cancer as new drug candidate

Read More

Astion Pharma initiates phase III clinical studies of ASF-1057 for seborrheic dermatitis

Read More

FDA grants approval to Resverlogix to initiate phase Ia clinical trial of RVX-208

Read More

Recent AstraZeneca and Argenta patents impart new therapeutic agents for respiratory disorders

Read More

Novel guanylate cyclase activators imparted in recent Bayer patent

Read More

ImmunoVaccine Technologies to acquire Immunotope

Read More

Mutant MOR gene transfer plus naloxone treatment leads to analgesia without tolerance in mice

Read More

Targacept initiates phase I clinical trial of TC-6499 for neuropathic pain

Read More

AVANIR initiates enrollment in phase III trial of Zenvia for pseudobulbar affect

Read More

Dia-B Tech reports positive results from phase I clinical study of ISF-402 for type 2 diabetes

Read More

Cobalamin oral insulin significantly reduces glucose in preclinical study

Read More

FDA grants orphan drug designation to GTC Biotherapeutics' ATryn

Read More

Wyeth Pharmaceuticals initiates phase I/II clinical trial of Trubion's TRU-015 for NHL

Read More

Celsion refiles for an FDA Special Protocol Assessment for phase III trial of ThermoDox

Read More

Medarex and Bristol-Myers report positive results from three registrational trials of ipilimumab

Read More

FDA grants approval to SKCC for phase I clinical trial of breast cancer vaccine

Read More

FDA advisory committee recommends approval of Kynapid for acute atrial fibrillation

Read More

Ono and Banyu submit Japanese approval application for sitagliptin for type 2 diabetes

Read More

Popular Stories

  • Today's news in brief

    BioWorld
  • Art concept for targeting the brain

    Precision psychiatry beyond, or before, biomarkers

    BioWorld
    There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
  • MRI image brain on black background

    ADPD 2026: Can we prevent dementia? Scientists quantify it

    BioWorld
    Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
  • First-in-class POLG activator restores mtDNA across mutations

    BioWorld Science
    Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 17, 2026
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing